Clinical research
BioSpace has put together a list of the top 10 indications that have been or are the subject of being researched across the region by pharma companies, academic institutions and other organizations. The trials range from Phase I to Phase III.
San Diego-based Mirati Therapeutics announced the first clinical data from its Phase I/II clinical trial of MRTX849 in solid tumors. MRTX849 is a KRAS G12C inhibitor.
The companies indicate that the decision was based on lack of efficacy, not any safety concerns.
Despite the success Gilead Sciences has seen with its JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.
Arcutis Also Announces Enrollment of Last Patient in 52-Week Long-term Safety Study of ARQ-151 Cream as a Potential Topical Treatment for Plaque Psoriasis
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
GeoVax Labs, Inc. announced its participation in a planned clinical trial led by researchers at American Gene Technologies, to develop a therapy aimed at eliminating HIV from infected people..
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
The new data could boost the company’s chances of securing regulatory approval.
MONROVIA, Calif., October 22, 2019 – AcuraStem, a biotechnology company advancing neuroscience through patient-based drug discovery, announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research grant awarded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health *[Award Number R44NS105156].
Houston, TX - BreviTest Technologies has been awarded a $1,500,000 grant from the National Institute on Drug Abuse of the National Institutes of Health to further the commercialization of its point-of-care analyzer for rapid opioid urine testing.
PRESS RELEASES